9th Advanced RWE Applications in Pharma

Returning for its 9th year, Advanced Real-World Evidence Applications in Pharma 2021 (formerly IMPACCT: RWE) will assist pharma and biotech leaders in transforming real-world evidence into business intelligence, impacting your pipeline, and delivering patient outcomes.
Across 3 days, you can expect 18+ practical case studies and a collaborative, open discussion to accelerate your implementation of real-world evidence approaches to enhance clinical R&D outcomes, de-risk clinical trials, and maximize product lifecycle.

What's New in 2021?

2020 was an exciting year for real-world data (RWD) and real-world evidence (RWE) experts within pharma and biotech. The FDA’s high-profile acceptance of RWD as part of their review for COVID-19 treatments and vaccines for emergency use authorization was a big moment for the industry. This is now energizing RWD and RWE into R&D and clinical activities – expediting novel treatments for patients and substantially reducing drug developers’ R&D spend.

However, major questions still need answers urgently. The 9th Advanced Real-World Evidence Applications in Pharma will return in October 2021 to delve into the core industry challenges, including:

- Assessing the global regulatory environment for future RWE application
- Advanced data acquisition and analytics to enable your R&D and clinically informed decision making
- Leverage RWE in your clinical activities – from patient selection to synthetic trial arm
- How to create a robust, regulatory-compliant RWE framework and data package for your successful IND filing
- Maximizing your product lifecycle through a comprehensive observational data program
- Establishing pre-competitive collaboration to deepen your understanding of diseases, offering patients a personalized and effective treatment through RWE and RWD

Your Unmissable Content:

- Designing an optimal and fit-for-purpose synthetic control arm for clinical trials – Robertino Mera-Giler, Freenome
- Adapting to survive the changing climate of the real-world research regulatory environment – Stuart McCully and Ken Ashman, Real-World Research Ltd.
- Reimagining your clinical trial by embracing real-world data – Paul Petraro, Beohringer Ingelheim
- Generating real-world evidence for COVID-19 treatments during a pandemic – Anand Chokkalingam, Gilead Sciences

Speakers: Charles Makin, Global Head, Medical Health, Outcomes Biogen, Kraig Kinchen, Senior Director, Center of Expertise, Global Patient Outcomes and Real World Evidence, Eli Lilly, Kelly Zou, Head of Global Medical Analytics and Real World Evidence, Viatris, Robertino Mera-Giler, Head Biostatistics, Epidemiology, RWE, Freenome Inc., Bindu Kalesan, Senior Director, Head of Clinical Epidemiology, Regeneron Genetic Center, Regeneron, Paul Petraro, Executive Director, Real World Evidence Analytic Centre of Excellence, Boehringer Ingelheim, Eric Sarpong, Director Real World Data Analytics and Innovation, Center for Observational and Real World Evidence, Merck, Lee Severson, Global Regulatory Lead, Global Product Strategy, CSL Behring, Angela Dobes, Vice President, IBD Plexus, Crohn’s and Colitis Foundation of America, Xia Wang, Director, Health Data Science, AstraZeneca, Lina Titievsky, Senior Director, RWE, Vertex Pharmaceuticals, Stuart Turner, Executive Director RWE and Data Science, Novartis, Ken Ashman, CEO, Real-World Research Ltd., Stuart McCully, CSO, Real-World Research Ltd., Samantha St. Laurent, Director, Oncology Cell and Gene Therapy, Value Evidence and Outcomes, GSK, Anand Chokkalingam, Senior Director, Clinical Research, Gilead Sciences, Yanni Hao, Executive Director, RWE and Data Science, Novartis, Rachele Hendricks- Sturrup, Research Director, Real World Evidence, Duke Margolis Center for Health Policy, Senior Representative, IQVIA, Senior Representative, OM1

Others Details

Brochure: https://go.evvnt.com/855566-3?pid=6581